Skip to Main Content
Skip Navigation Links

Press Room & News Hospital News

Top Cancer Doc Joins Hospital

Dr. Joseph Rosenthal Brings Wealth of Experience as Children’s new Medical Director, Pediatric Hematology/Oncology


A national expert in the field of pediatric hematology/oncology and stem cell transplant, Dr. Joseph Rosenthal, joins Children’s Hospital Central California as the new medical director of pediatric hematology/oncology.

Dr. Joseph RosenthalA well-respected clinician and researcher with extensive experience in pediatric clinical trials and transplant studies, Dr. Rosenthal has led numerous studies investigating novel treatments for many hematologic malignancies. He brings 30 years of pediatric medical expertise to the Central Valley in treating childhood cancer, other life-threatening hematological disorders and long-term consequences of treatment.

Dr. Rosenthal comes to Children’s from City of Hope, National Medical Center in Duarte, Calif., where he served as acting chair of the department of pediatrics, director of the pediatric hematopoietic cell transplantation program and professor of pediatrics. Dr. Rosenthal joined City of Hope in 1996 following a decade of experience in pediatric hematology and oncology research and treatment in Israel.

“Dr. Rosenthal’s wealth of experience and determined leadership style will help further build our reputation nationally and explore other opportunities to advance the care of children in our region,” said Dr. David Christensen, Children’s vice president medical affairs and chief medical officer.

Children’s breadth of specialized services and depth of experience enable the multidisciplinary team at Children’s Craycroft Cancer Center to treat childhood cancer from the most common to the rarest conditions. Dr. Rosenthal looks forward to helping Craycroft’s already strong, dedicated team of eight pediatric hematologists/oncologists become even stronger.

“I was already familiar with many of the hematologists/oncologists at Children’s while I was at City of Hope,” said Dr. Rosenthal. “They’re a talented, enthusiastic team. They were my colleagues and now they’re my partners in providing quality care for kids.”

In fact, ensuring that every child in the Hospital’s 45,000-square-mile area from Los Angeles to the Bay Area has access to exceptional pediatric medical care is a top priority for Dr. Rosenthal: “The Central Valley has a lot of underserved children. Delivering high-quality care to all children is an issue close to my heart.”

Dr. Rosenthal said he is particularly impressed with the Hospital’s well-developed hematology and solid tumor programs, including the recent addition of neuro-oncologist, Dr. David Samuel, who specializes in brain and nervous system cancers. Dr. Rosenthal is also interested in continuing to expand Craycroft’s long-term survivor program that addresses former cancer patients’ health issues resulting from cancer treatments.

“Long-term follow-up care has become more important as more pediatric cancer patients are surviving longer,” said Dr. Rosenthal. “The medical community cared for these patients and we have a responsibility to help treat the ailments created by that treatment.”

Board certified in pediatric hematology/oncology, Dr. Rosenthal received his medical degree from Tel Aviv University in Israel and holds a master of science degree in healthcare management from the Harvard School of Public Health in Boston, Mass. His postdoctoral training includes completing a fellowship in pediatric hematology/oncology at The Children’s Hospital near Denver, Colo., and a fellowship in pediatric cancer research and bone marrow transplantation at Children’s Hospital of Orange County in Orange, Calif.

He has published his work in numerous peer-reviewed journals such as “Blood,” “Journal of Pediatrics,” “Journal of Clinical Oncology,” “International Journal of Pediatric Hematology/Oncology,” “Archives of Pediatrics and Adolescent Medicine,” “Pediatric Blood and Cancer” and “Biol Blood Marrow Transplant.”

Dr. Rosenthal is a member of several professional societies, including the American Society of Clinical Oncology, the American Society for Blood and Marrow Transplantation and the American Society of Hematology. He is also a member of Specialty Medical Group.